• Product NameI-CBP112 hydrochloride
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityI-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors respectively). I-CBP112 has little activity against other bromodomains at concentrations up to 1 mM. I-CBP112 targets the CBP/p300 bromodomains. I-CBP112 significantly reduced the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. Interestingly, I-CBP112 increased the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin.
• Target NameEpigenetic Reader Domain inhibitor
• CAS No. T4247
• Calculated MW 505
• Formulation C27H36N2O5HCl
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:CCC(=O)N1CCOC2=C(C1)C=C(C=C2OC[C@H]3CCCN(C3)C)C4=CC(=C(C=C4)OC)OC.Cl
  Pathways:Chromatin/Epigenetic
  Receptor:CBP/p300, Leukemia cell; CBP/p300, Prostate cancer cell
  Boling pt:
  Melting pt:
  Solubility:DMSO: 32 mg/mL
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Zucconi BE, et al. Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain LigandI-CBP112. Biochemistry. 2016 Jul 12;55(27):3727-34.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting